Evidence map›Paper›PMID 29160745›Full record

ReviewCell cycle (Georgetown, Tex.)2018

The unveiling of the Warburg effect and the inscribed innovative approach to a radical non toxic anticancer therapy.

Olivia Crociani, Ilaria Marzi, Maria Grazia Cipolleschi, Antonella Mannini, Massimo Contini, Massimo Olivotto

Open access · hybridAbstract readReview
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Olivia Crocianib Department Experimental and Clinical Medicine , University of Firenze , Viale Morgagni , 50-50134 , Italy.ORCID 0000-0003-3485-2132
Ilaria Marzia Department Biomedical, Experimental and Clinical Sciences , University of Firenze , Viale Morgagni , 50-50134 , Italy.ORCID 0000-0001-6525-1247
Maria Grazia Cipolleschia Department Biomedical, Experimental and Clinical Sciences , University of Firenze , Viale Morgagni , 50-50134 , Italy.ORCID 0000-0003-4454-3771
Antonella Manninib Department Experimental and Clinical Medicine , University of Firenze , Viale Morgagni , 50-50134 , Italy.ORCID 0000-0002-3173-8089
Massimo Continib Department Experimental and Clinical Medicine , University of Firenze , Viale Morgagni , 50-50134 , Italy.ORCID 0000-0001-9555-2366
Massimo Olivottoa Department Biomedical, Experimental and Clinical Sciences , University of Firenze , Viale Morgagni , 50-50134 , Italy.ORCID 0000-0003-2766-0781
University of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this research has been deciphering the Warburg paradox, the biochemical enigma unsolved since 1923. We solved it by demonstrating that its specific character, i.e. the forced aerobic lactate exportation, represents a crucial metabolic device to counteract the cytotoxic effect produced by an excess of pyruvate at the connection of glycolysis with the Krebs cycle. This solution was verified by exposing cancer cells of different histogenesis to pyruvate concentrations higher than the physiological ones, after showing that these concentrations are totally innocuous when injected into mice. The mechanism of the pyruvate cytotoxicity relies on the saturation of the respiratory chain, leading to a negative shift of the cytosolic NADP/NADPH ratio and the consequent restriction of the purine synthesis and the related cell apoptosis. The reducing equivalents generated by glycolysis and by cytosolic metabolism compete each other for their disposal trough the respiratory chain; this makes it that the cytotoxicity of pyruvate is inversely related to the mitochondrial number and efficiency of various cell types. Thus, the cytotoxicity is high in anaplastic cancer stem cells, whose mitochondria are extremely few and immature (cristae-poor); on the contrary, no inhibition is brought about in adult differentiated cells, physiologically rich of mature mitochondria. All this generates the pyruvate anticancer selectivity, together with the lack of a general toxicity, making pyruvate represent an ideal candidate for a radical non toxical anticancer treatment.

Indexed as

AnimalsAntineoplastic AgentsGlycolysisHumansMitochondriaNeoplasmsNeoplastic Stem CellsTumor HypoxiaAntineoplastic Agentsmitochondrial featuresNADP/NADPH ratiopyruvate cytotoxicitystem cell targetingWarburg effect

Identifiers

PMID29160745
PMCPMC5914906
OpenAlexW2768782690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.